Table 1

Baseline demographic and disease characteristics of the study population

CharacteristicsStudy population n=44GLM+MTX
n=21
PLB+MTX
n=23
Male gender, n (%)37 (84.0%)17 (81.0%)20 (87.0%)
Age at randomisation, years, median (IQR)45.7 (19.6)46.2 (15.5)44.1 (24.6)
Disease duration, median (IQR)3.9 (6.9)3.8 (6.7)4.2 (6.1)
Body mass index (kg/m2), median (IQR)26.6 (6.1)29.0 (4.5)25.9 (5.4)
Clinical subtype, n (%)
 Symmetric polyarthritis9 (20.5)5 (23.8)4 (17.4)
 Predominant arthritis of the distal interphalangeal joints3 (6.8)2 (9.5)1 (4.3)
 Asymmetric oligoarthritis31 (70.5)13 (61.9)18 (78.3)
 Arthritis mutilans0 (0)0 (0)0 (0)
 Predominant axial1 (2.3)1 (4.8)0 (0)
Dactylitis
 DSS, median (IQR)6 (4)6 (5)6 (3.5)
 LDI, median (IQR)64.7 (81.7)69.4 (73.8)64.0 (100)
Enthesitis
 Enthesitis, median (IQR)1 (2)1 (2)1 (2)
 Enthesitis ≥1 n (%)23/44 (52.3%)11/21 (52.4%)12/23 (52.2%)
 LEI, median (IQR)0 (1)0 (1)0 (1)
 LEI≥1, n (%)16/44 (36.4%)7/21 (33,3%)9/23 (39,1%)
 SPARCC, median (IQR)1 (2)1 (2)1 (2)
 SPARCC≥1, n (%)23/44 (52.3%)11/23 (47.8%)12/23 (52.2%)
Peripheral joints
 Tender joints (68), median (IQR)7.5 (9.25)8 (9)6 (8)
 Swollen joints (66), median (IQR)6.5 (6.5)7 (10)6 (5)
Psoriasis
 PASI, median (IQR)3.05 (4.3)4 (4)2.4 (2.65)
 BSA, median (IQR)9.75 (21.6)13 (29.5)8.2 (15.3)
 Target NAPSI, median (IQR)4 (8)4 (10)4 (5)
Physical function
 HAQ-DI, median (IQR)0.875 (IQR)0.875 (0.625)0.875 (1.25)
Health-related quality of life
 DLQI, median (IQR)3 (4.25)4 (4)1 (4)
Composite indices of disease activity
 DAS28 4v, median (IQR)4.01 (1.68)3.71 (0.96)4.14 (1.99)
 DAPSA, median (IQR)24.41 (21.31)24.3 (20.84)24.5 (20.20)
 PASDAS, median (IQR)6.13 (2.35)6.1 (1.83)6.2 (2.58)
 CPDAI, median (IQR)11 (I3.5)11.0 (3.5)11.5 (2.5)
  • BSA, body surface area; CPDAI, Composite Psoriatic Disease Activity Index; DAPSA, disease activity in psoriatic arthritis; DAS28 4v, Disease Activity Score 4 variablesDLQI, Dermatology Life Quality Index; DSS, Dactylitis Severity Score; GLM, golimumab; HAQ-DI, Health Assessment Questionnaire Disability Index; LDI, Leeds Dactylitis Index; LEI, Leeds Enthesitis Index; MTX, methotrexate; NAPSI, Nail Psoriasis Severity Index; PASDAS, Psoriatic Arthritis Disease Activity Score; PASI, Psoriasis Area and Severity Index; PLB, placebo; SPARCC, Spondyloarthritis Research Consortium of Canada Enthesitis Index;BSA, body surface area; BSA, body surface area; CPDAI, Composite Psoriatic Disease Activity Index; CPDAI, Composite Psoriatic Disease Activity Index; DAPSA, disease activity in psoriatic arthritis; DAPSA, disease activity in psoriatic arthritis; DAS28 4v, Disease Activity Score 4 variablesDAS28 4v, Disease Activity Score 4 variablesDLQI, Dermatology Life Quality Index; DLQI, Dermatology Life Quality Index; DSS, Dactylitis Severity Score; DSS, Dactylitis Severity Score; GLM, golimumab; GLM, golimumab; HAQ-DI, Health Assessment Questionnaire Disability Index; HAQ-DI, Health Assessment Questionnaire Disability Index; LDI, Leeds Dactylitis Index; LDI, Leeds Dactylitis Index; LEI, Leeds Enthesitis Index; LEI, Leeds Enthesitis Index; MTX, methotrexate; MTX, methotrexate; NAPSI, Nail Psoriasis Severity Index; NAPSI, Nail Psoriasis Severity Index; PASDAS, Psoriatic Arthritis Disease Activity Score; PASDAS, Psoriatic Arthritis Disease Activity Score; PASI, Psoriasis Area and Severity Index; PASI, Psoriasis Area and Severity Index; PLB, placebo; PLB, placebo; SPARCC, Spondyloarthritis Research Consortium of Canada Enthesitis Index; SPARCC, Spondyloarthritis Research Consortium of Canada Enthesitis Index.